Corcept Therapeutics Newswire (Page 4)

Corcept Therapeutics Newswire (Page 4)

Comprehensive Real-Time News Feed for Corcept Therapeutics. (Page 4)

Results 61 - 80 of 93 in Corcept Therapeutics

  1. Corcept Therapeutics Inc. Announces Initial Efficacy Results In Phase ...Read the original story

    Dec 14, 2015 | BioSpace

    Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating activity at the glucocorticoid receptor , presented initial efficacy data from its Phase 1/2 trial of mifepristone in combination with the chemotherapy drug eribulin to treat patients with GR-positive, metastatic, triple-negative breast cancer . The data were presented at the 2015 San Antonio Breast Cancer Symposium on Saturday, December 12th, 2015.

    Comment?

  2. Corcept Therapeutics Incorporated (CORT) Stock Price Down 6.5% on Insider SellingRead the original story w/Photo

    Dec 14, 2015 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated was down 6.5% on Monday after an insider sold shares in the company, Analyst Ratings Net reports. The stock traded as low as $4.33 and last traded at $4.45, with a volume of 295,089 shares traded.

    Comment?

  3. Corcept Therapeutics Incorporated (CORT) Director Sells $97,000.00 in StockRead the original story w/Photo

    Dec 11, 2015 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated Director Daniel Bradbury sold 20,000 shares of the firm's stock in a transaction dated Thursday, December 10th. The stock was sold at an average price of $4.85, for a total value of $97,000.00.

    Comment?

  4. Corcept Therapeutics Director Sells $200,000.00 in StockRead the original story

    Nov 25, 2015 | AmericanBankingNews.com

    Corcept Therapeutics Director Daniel Bradbury sold 40,000 shares of the company's stock in a transaction on Tuesday, November 24th. The shares were sold at an average price of $5.00, for a total value of $200,000.00.

    Comment?

  5. Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Nov 5, 2015 | Seeking Alpha

    Hello and welcome to the Corcept Therapeutics conference call. [Operator Instructions] Please note this conference is being recorded.

    Comment?

  6. Corcept Therapeutics Trading Up 6% After Strong EarningsRead the original story

    Nov 6, 2015 | AmericanBankingNews.com

    Shares of Corcept Therapeutics were up 6% during mid-day trading on Friday following a better than expected earnings announcement, MarketBeat Ratings reports. The stock traded as high as $4.49 and last traded at $4.43, with a volume of 115,867 shares.

    Comment?

  7. Corcept Therapeutics VP Steven Lo Sells 12,500 SharesRead the original story

    Nov 4, 2015 | AmericanBankingNews.com

    Corcept Therapeutics VP Steven Lo sold 12,500 shares of Corcept Therapeutics stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $4.00, for a total transaction of $50,000.00.

    Comment?

  8. Corcept Therapeutics Inc. To Announce Third Quarter Financial Results ...Read the original story

    Oct 29, 2015 | BioSpace

    Corcept Therapeutics Incorporated today announced it will report third quarter financial results and provide a corporate update on November 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time .

    Comment?

  9. Analysts Anticipate Corcept Therapeutics to PostRead the original story

    Oct 21, 2015 | AmericanBankingNews.com

    Corcept Therapeutics has earned an average broker rating score of 2.00 from the three brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a sell recommendation and two have given a strong buy recommendation to the company.

    Comment?

  10. Insider Selling: Steven Lo Sells 53,033 Shares of Corcept Therapeutics StockRead the original story

    Oct 15, 2015 | AmericanBankingNews.com

    Corcept Therapeutics VP Steven Lo sold 53,033 shares of the business's stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $3.82, for a total value of $202,586.06.

    Comment?

  11. Corcept Therapeutics Inc. Release: Results Of Phase 1 Trial Of...Read the original story

    Oct 13, 2015 | BioSpace

    Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced today that a poster describing the Phase 1 trial results of its next-generation cortisol modulator CORT125134 will be presented at the annual meeting of the American Association of Pharmaceutical Scientists in Orlando, Florida on October 28, 2015.

    Comment?

  12. Results of Phase 1 Trial of Next-Generation Cortisol Modulator...Read the original story

    Oct 13, 2015 | Freshnews

    10/13/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced today ...

    Comment?

  13. Corcept Therapeutics's Outperform Rating Reiterated at FBR & Co.Read the original story

    Oct 12, 2015 | AmericanBankingNews.com

    ... a potential upside of 220.86% from the company's current price. Separately, Zacks downgraded shares of Corcept Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, June 22nd. In other Corcept Therapeutics news, VP ...

    Comment?

  14. Corcept Therapeutics Lifted to "Buy" at ZacksRead the original story

    Oct 11, 2015 | AmericanBankingNews.com

    ... next most advanced pipeline candidate is CORT125134, scheduled to move into phase II next year." Corcept Therapeutics ( NASDAQ:CORT ) traded down 1.32% during midday trading on Wednesday, hitting $3.74. The company had a trading volume of 188,305 ...

    Comment?

  15. Corcept Therapeutics VP Sells $21,200.00 in StockRead the original story

    Oct 9, 2015 | AmericanBankingNews.com

    Corcept Therapeutics VP Steven Lo sold 5,300 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $4.00, for a total transaction of $21,200.00.

    Comment?

  16. These Insider Sales Could Indicate That The Bull Market Has Run Its CourseRead the original story w/Photo

    Oct 8, 2015 | Insider Monkey

    ... Dave & Buster's Entertainment Inc. (NASDAQ: PLAY ) , Frequency Electronics Inc. (NASDAQ: FEIM ) , and Corcept Therapeutics Incorporated (NASDAQ: CORT ) . It is also worth pointing out that we do not consider the sales conducted under trading plans, ...

    Comment?

  17. Insider Selling: Corcept Therapeutics VP Sells 50,000 Shares of StockRead the original story

    Oct 7, 2015 | AmericanBankingNews.com

    Corcept Therapeutics VP Steven Lo sold 50,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $3.76, for a total value of $188,000.00.

    Comment?

  18. Accelerating Timelines From Candidate Selection to Proof-of-Concept...Read the original story w/Photo

    Sep 30, 2015 | Market Wire

    ... Director of Exploratory Clinical Pharmacology at Quotient Clinical, and Hazel Hunt, VP of Research at Corcept Therapeutics, will discuss the Enabled-FIH approach designed specifically to address these requirements. There will be two live broadcasts, ...

    Comment?

  19. Corcept Therapeutics Inc. Appoints M.D., As Chief Medical OfficerRead the original story

    Sep 28, 2015 | BioSpace

    Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced today that Robert S. Fishman, M.D., has joined the company as its Chief Medical Officer. "I am very happy to welcome Bob to Corcept," said Joseph K. Belanoff, M.D., the company's Chief Executive Officer.

    Comment?

  20. New Market Research Report: Corcept Therapeutics IncorporatedRead the original story w/Photo

    Sep 27, 2015 | PR-inside.com

    Corcept Therapeutics Incorporated is a research focused pharmaceutical company. It carries out discovery development and commercialization of innovative therapeutics in the areas of psychiatric and metabolic diseases.

    Comment?